Secondary Central Nervous System Lymphoma Clinical Trials

15 clinical trials for Secondary Central Nervous System Lymphoma across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) — RECRUITING · PHASE1
• Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma — RECRUITING · PHASE1
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) — RECRUITING · PHASE1
• Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies — RECRUITING
• Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma — RECRUITING · PHASE1
• Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas — RECRUITING · PHASE2
• PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. — RECRUITING · PHASE2
• Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma — SUSPENDED · PHASE1
• Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) — ACTIVE_NOT_RECRUITING · PHASE2
• Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) — COMPLETED · PHASE1
• A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL — OTHER · PHASE2
• R-MTX-zanbrutinib in Secondary CNS Lymphoma — OTHER · PHASE2
• A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) — OTHER · PHASE2

Refine this search